Objective
To study the mRNA expressions of various CD97 isoforms in colorectal carcinoma tissues and their clinical significances.
Methods
A total of 50 colon cancer patients in the First Affiliated Hospital of Wenzhou Medical University from December 2013 to May 2014 and human colon cancer cell lines SW480 and SW620 were enrolled. The real-time fluorescence quantitative polymerase chain reaction (qRT-PCR) was used to detect the mRNA expressions of CD97 human epidermal growth factor (EGF) (1, 2, 5), CD97EGF (1, 2, 3, 5) and CD97EGF (1, 2, 3, 4, 5) in colon cancer tissues, adjacent tissues, normal colon tissues, SW480 cells and SW620 cells. The relationship between the mRNA expression of CD97EGF (1, 2, 5) and the clinicopathological factors was analyzed.
Results
Compared with those low expressions in adjacent tissues and normal tissues, the mRNA expressions of CD97 isoforms CD97EGF (1, 2, 5), CD97EGF (1, 2, 3, 5) and CD97EGF (1, 2, 3, 4, 5) in cancer tissues were highest, and the differences were statistically significant (0.71±0.20 vs. 0.40±0.09 vs. 0.35±0.07, F = 107.642, P < 0.01; 0.45±0.11 vs. 0.26±0.05 vs. 0.27±0.06, F = 94.231, P < 0.01; 0.41±0.10 vs. 0.21±0.05 vs. 0.19±0.03, F = 165.672, P < 0.01). In addition, the mRNA expression of CD97EGF (1, 2, 5) in colon cancer patients was associated with tumor infiltration depth (T1-T2 and T3-T4), clinical stages (Ⅰ-Ⅱ and Ⅲ-Ⅳ), and the differences were statistically significant (t = -2.582, P = 0.013; t = -5.062, P < 0.01). The mRNA expression of CD97EGF (1, 2, 5) in SW620 cells was higher than that in SW480 cells.
Conclusions
CD97 isoforms are highly expressed in colon cancer tissues, and CD97EGF (1, 2, 5) may play an important role in the development and invasion of colon cancer. The CD97 isoforms may be new markers in the treatment of colon cancer.
Key words:
Colonic neoplasms; Isoform, CD97; Reverse transcriptase polymerase chain reaction; Pathology, clinical
IntroductionWe aimed to analyze the psychological status in patients with breast cancer (BC) in the epicenter of the coronavirus disease 2019 (COVID-19) pandemic.Patients and MethodsA total of 658 individuals were recruited from multiple BC centers in Hubei Province. Online questionnaires were conducted, and these included demographic information, clinical features, and 4 patient-reported outcome scales (Generalized Anxiety Disorder Questionnaire [GAD-7], Patient Health Questionnaire [PHQ-9], Insomnia Severity Index [ISI], and Impact of Events Scale-Revised [IES-R]). Multivariable logistic regression analysis was designed to identify potential factors on mental health outcomes.ResultsQuestionnaires were collected from February 16, 2020 to February 19, 2020, the peak time point of the COVID-19 outbreak in China. Of patients with BC, 46.2% had to modify planned necessary anti-cancer treatment during the outbreak. Severe anxiety and severe depression were reported by 8.9% and 9.3% of patients, respectively. Severe distress and insomnia were reported by 20.8% and 4.0% of patients, respectively. Multivariable logistic regression analysis demonstrated poor general condition, shorter duration after BC diagnosis, aggressive BC molecular subtypes, and close contact with patients with COVID-19 as independent factors associated with anxiety. Poor general condition and central venous catheter flushing delay were factors that were independently associated with depression. In terms of insomnia, poor generation condition was the only associated independent factor. Poor physical condition and treatment discontinuation were underlying risk factors for distress based on multivariable analysis.ConclusionHigh rates of anxiety, depression, distress, and insomnia were observed in patients with BC during the COVID-19 outbreak. Special attention should be paid to the psychological status of patients with BC, especially those with poor general condition, treatment discontinuation, aggressive molecular subtypes, and metastatic BC.
Abstract Background: Some patients with breast cancer are diagnosed with locally advanced breast cancer (LABC). At present, there are no obvious reports on LABC radiotherapy, chemotherapy, and breast-conserving benefit population. Method: The cases of LABC confirmed by pathology from 2010 to 2015 were searched through the Surveillance Epidemiology and End Results (SEER) database. Breast cancer-specific survival (BCSS) and overall survival (OS) were estimated by plotting Kaplan-Meier curves. The log rank test (Mantel-Cox) was used to analyze the difference between the groups, and the benefit population of LABC was determined after for age, TNM stage, grade, treatment methods. Results: A total of 34474 LABC patients were included, 22477 (65.2%) were Luminal A, 1418 (4.1%) were Luminal B, 4911 (14.3%) were triple-negative breast cancer, 2461 (7.1%) were HER2-enriched, and 3207 (9.3%) were three positive breast cancer. Kaplan-Meier curves of 5-year OS and BCSS were plotted for LABC patients with different molecular types of breast conserving surgery and mastectomy. Overall the LABC with breast conserving and total mastectomy was 77.8%, 84.6% ,68.4% and 77.2%. Luminal A LABC with breast conserving and total mastectomy was 79.9%,87.5%, 72.3% and 81.5%.Luminal B LABC with breast-conserving and total mastectomy were 79.3% , 83.1%, 70.8% and 77.1%. TNBC LABC with breast-conserving and total mastectomy were 61.0% ,68.4%, 47.5% and 56.2%. HER2-enriched LABC with breast-conserving and total mastectomy were 77.7%, 80.5%, 67.2% and 75.2%. TPBC LABC with breast-conserving and total mastectomy were 84.9%, 91.8%, 75.5% and 82.1%, respectively. Except for the Luminal B LABC BCSS surgery method, there was no significant difference (P=0.058), all the others were statistically significant (P<0.05). Conclusions: This study found that in the selective population, OS and BCSS of patients with LABC undergoing breast conserving surgery were significantly better than those of mastectomy.This study also found that LABC could be considered for highly differentiated, NO stage TPBC without chemotherapy.
Nipple-sparing mastectomy (NSM) offers superior cosmetic outcomes and has been gaining wide acceptance. It has always been difficult to objectively quantify the risk of nipple-areola complex involvement (NACi). The goal was to develop a prediction model for clinical application.Patients who had a total mastectomy (TM) between January 2016 and January 2020 at a single institute formed the development cohort (n = 578) and those who had NSM + immediate breast reconstruction (IBR) between January 2020 and January 2021 formed the validation cohort (n = 112). The prediction model was developed using univariate and multivariate logistic regression studies. Based on NACi risk variables identified in the development cohort, a nomogram was created and evaluated in the validation cohort. Meanwhile, stratified analysis was performed based on the model's risk levels and was combined with intraoperative frozen pathology (IFP) to optimize the model.Tumor central location, clinical tumor size (CTS) > 4.0 cm, tumor-nipple distance (TND) ≤ 1.0 cm, clinical nodal status positive (cN +), and KI-67 ≥ 20% were revealed to be good predictive indicators for NACi. A nomogram based on these major clinicopathologic variables was employed to quantify preoperative NACi risk. The accuracy was verified internally and externally. The diagnostic accuracy of IFP was 92.9%, sensitivity was 64.3%, and specificity was 96.9% in the validation group. Stratified analysis was then performed based on model risk. The diagnostic accuracy rates of IFP and NACiPM in low-risk, intermediate-risk, and high-risk respectively were 96.0%, 93.3%, 83.9%, 61.3%, 66.7%, and 83.3%.We created a visual nomogram to predict NACi risk in breast cancer patients. The NACiPM can be used to distinguish the low, intermediate, and high risk of NAC before surgery. Combined with IFP, we can develop a decision-making system for the implementation of NSM.
Objective
To explore the application of osteopontin (OPN) and Stathmin-1 expression in the evaluation of prostate cancer recurrence and survival prognosis.
Methods
One hundred patients with prostate cancer were selected from June 2014 to June 2016. The expressions of OPN and Stathmin-1 in prostate cancer tissue were detected by immunohistochemical staining SP method, and its correlation with clinicopathological features was analyzed.
Results
The OPN positive expression in prostate cancer tissue was in 76 cases (76.00%, 76/100), the Stathmin-1 positive expression in prostate cancer tissue was in 79 cases (79.00%, 79/100), and both the OPN and Stathmin-1 positive expression in prostate cancer tissue was in 60 cases (60.00%, 60/100). Spearman correlation analysis result showed that the expression of OPN in prostate cancer tissue had positive correlation with Stathmin-1 (r= 0.491, P 0.05). The survival time in OPN positive expression, Stathmin-1 positive expression and both OPN/Stathmin-1 positive expression was (18.45 ± 2.03), (17.95 ± 2.01) and (15.24 ± 1.72) months; the survival time in OPN negative expression, Stathmin-1 negative expression and OPN/Stathmin-1 single positive or both negative was (24.67 ± 2.62), (23.79 ± 2.58) and (26.68 ± 2.72) months, and there was statistical difference (P<0.05).
Conclusions
The OPN and Stathmin-1 expressions in prostate cancer tissue are high, and show relations with Gleason score, bone metastases and T staging, and no correlation with recurrence. But OPN and Stathmin-1 can provide reference for survival in patients with prostate cancer prognosis assessment.
Key words:
Prostatic neoplasms; Osteopontin; Recurrence; Prognosis; Retrospective studies
How to safely and effectively locate, select and dissect the perforator vessels is the biggest difficulty in the preparation of DIEP flap. Preoperative CTA was used to evaluate the perforators of the DIEP flap. The CTA data were imported into the image analysis software to select the dominant perforators of the flap before operation, and to determine the anatomical information such as the diameter of the perforator vessel, the course of the perforator in the muscle, and the location of the perforator exit point, so as to guide the operation. In summary, CTA technology can accurately provide detailed anatomical information of perforator vessels, facilitate surgical design, reduce intraoperative perforator selection and dissection time, reduce the risk of secondary surgical exploration, and have a high imaging and surgical consistency rate, especially for patients with a history of abdominal surgery, CTA is of higher value. Therefore, CTA examination is worthy of clinical application in delayed DIEP breast flap reconstruction.
The cross-domain fault diagnosis method based on domain adaptation is a hot topic in recent years. It is difficult to collect a complete data set containing all fault categories in practice under the same working condition, leading to fault categories knowledge loss in the single source domain. To resolve the problem, a cross-domain fault diagnosis method with multi-source incomplete data is proposed in this study. First, the cycle generative adversarial network is used to learn the mapping between multi-source domains to complement the missing category data. Then, considering the domain mismatch problem, a multi-source domain adaption model based on anchor adapters is developed to obtain general domain invariant diagnosis knowledge. Finally, the fault diagnosis model is established by an ensemble of multi-classifier results. Extensive experiments on bearing data sets demonstrate that the proposed method in cross-domain fault diagnosis with multi-source incomplete data is effective and has a good diagnosis performance.
'/%3e%3cuse xlink:href='%23a' transform='rotate(23.036 .093 25.536)'/%3e%3cuse xlink:href='%23a' transform='rotate(45.87 1.273 16.18)'/%3e%3cuse xlink:href='%23a' transform='rotate(69.945 .996 12.078)'/%3e%3cuse xlink:href='%23a' transform='rotate(20.66 -19.689 31.932)'/%3e%3c/svg%3e)